Weekly Paclitaxel Regimen: Dosing, Indications, and Management
Recommended Dosing Schedule
The standard weekly paclitaxel regimen is 80 mg/m² IV over 1 hour on days 1,8, and 15 of a 28-day cycle 1. This dose-dense schedule is a Category 1 recommendation across multiple NCCN guidelines and represents the most widely validated weekly approach.
Alternative weekly dosing options include:
- 80-90 mg/m² IV weekly for breast cancer (single agent or with trastuzumab) 1
- 90 mg/m² IV on days 1,8, and 15 every 28 days when combined with bevacizumab 1
- 60 mg/m² IV weekly for 18 weeks when combined with carboplatin AUC 2 (ovarian cancer) 2
The 1-hour infusion duration is safe and effective, simplifying outpatient administration compared to the traditional 3-hour infusion 3.
Primary Indications
Weekly paclitaxel is indicated for:
Breast Cancer
- Metastatic disease (single agent): 80 mg/m² weekly 1
- HER2-positive disease with trastuzumab: 80-90 mg/m² weekly 1
- Adjuvant therapy: Following anthracycline-cyclophosphamide (AC), give 175 mg/m² every 3 weeks for 4 cycles 4
- With bevacizumab: 90 mg/m² on days 1,8,15 every 28 days 1
Ovarian Cancer
- First-line therapy (dose-dense): 80 mg/m² on days 1,8,15 with carboplatin AUC 5-6 on day 1, every 3 weeks × 6 cycles (Category 1) 2
- Weekly continuous: 60 mg/m² weekly for 18 weeks with carboplatin AUC 2 (Category 1) 2
Non-Small Cell Lung Cancer
- Combination with carboplatin: 80 mg/m² on days 1,8,15 with carboplatin AUC 2, every 28 days 1
Other Malignancies
- Advanced gastric cancer: 80 mg/m² weekly for 3 weeks, followed by 1 week rest 5
- Various pretreated solid tumors: 90 mg/m² weekly for 6 weeks, followed by 2-3 week rest 6
Common Adverse Effects and Grading
Hematologic Toxicity
Weekly paclitaxel demonstrates remarkably low myelosuppression compared to every-3-week schedules 7, 6:
- Grade 3/4 neutropenia: 4-15% of patients
- Febrile neutropenia: rare (<2%)
- No cumulative myelosuppression with sustained weekly therapy 7
Peripheral Neuropathy
This is the dose-limiting toxicity for weekly paclitaxel 8, 7:
- Any grade: 46-87% depending on cumulative dose
- Grade 3: 2-21%
- Dose-dependent and cumulative
- Prevents escalation above 100 mg/m² weekly 7, 6
Hypersensitivity Reactions
- Occur in 9-16% with standard premedication 8
- Severe reactions (Grade 3/4): <1-2%
- No increased risk with 1-hour vs 3-hour infusions 3
Other Toxicities
- Myalgia/arthralgia: 21-60%, typically Grade 1-2 8
- Alopecia: 46-96% 8
- Mucositis: 17-37%, usually mild 8
- Nausea/vomiting: 65-93%, manageable with antiemetics 8
Toxicity Management
Premedication Protocol
Mandatory before each infusion 8:
- Dexamethasone 20 mg IV (or 10 mg for weekly dosing) 30-60 minutes prior
- Diphenhydramine 50 mg IV
- H2-antagonist (cimetidine 300 mg or ranitidine 50 mg) IV
Dose Modifications for Neuropathy
Grade 2 (moderate symptoms): Reduce dose by 20% (from 80 to 64 mg/m²)
Grade 3 (severe symptoms interfering with function): Hold treatment until recovery to Grade 1, then resume at 50% dose reduction
Grade 4: Discontinue paclitaxel permanently
Dose Modifications for Neutropenia
Neutrophils <1,500/mm³ on treatment day: Hold dose until recovery to ≥1,500/mm³
Febrile neutropenia or Grade 4 neutropenia >7 days: Reduce subsequent doses by 20%
G-CSF support is rarely needed with weekly dosing but can be considered for recurrent delays 7
Hemorrhagic Cystitis (Rare)
A recently reported adverse event with nab-paclitaxel 9:
- Monitor for hematuria, dysuria, urinary frequency
- Ensure adequate hydration
- Consider urologic consultation if symptoms develop
Critical Monitoring Parameters
Before Each Weekly Dose
- CBC with differential: Hold if ANC <1,500/mm³ or platelets <100,000/mm³
- Neurologic assessment: Document sensory/motor symptoms using standardized grading
- Vital signs: Monitor for hypersensitivity during and 30 minutes post-infusion
Periodic Monitoring
- Liver function tests: Baseline and as clinically indicated (paclitaxel is hepatically metabolized)
- Cardiac function: Baseline ECG if prior anthracycline exposure or cardiac risk factors
- Performance status: Assess functional capacity at each cycle
Important Clinical Pearls
Advantages of Weekly Dosing
- Superior tolerability: Minimal myelosuppression allows sustained therapy without breaks 7
- Dose-dense delivery: Higher cumulative dose intensity (91 mg/m²/week achievable) 7
- Outpatient-friendly: 1-hour infusion reduces clinic time and costs 3
- Maintained efficacy: Response rates of 20-65% in various malignancies 10
Common Pitfalls to Avoid
- Don't use BSA capping: Calculate full dose based on actual BSA (though some protocols cap at BSA 2.0 m² for IP therapy) 11
- Don't delay for mild neuropathy: Grade 1 neuropathy doesn't require dose modification
- Don't omit premedication: Even with weekly dosing, hypersensitivity risk persists
- Don't ignore cumulative neuropathy: Assess carefully at each visit; it's irreversible if severe
Drug Interactions
- CYP3A4 inhibitors (ketoconazole, ritonavir): May increase paclitaxel levels and toxicity
- CYP3A4 inducers (rifampin, phenytoin): May decrease efficacy
- Anthracyclines: Never give concurrently due to cardiotoxicity risk 4
Special Populations
Elderly patients: Weekly dosing particularly advantageous due to lower hematologic toxicity 4
Prior anthracycline exposure: 50% response rate maintained even in anthracycline-refractory disease 7
Performance status 2: Weekly regimen feasible; consider starting at lower dose (60-70 mg/m²)